Stocks to Watch as Investors Monitor Omicron Variant

Covid-19 cases are surging worldwide and a number of countries have imposed fresh restrictions in an effort to curb the spread of a new strain of the virus first identified in South Africa.

The discovery of the heavily mutated variant, called Omicron, spooked global markets last week.


The worldwide case count stood at more than 266.8 million Tuesday afternoon, with more than 5.27 million reported deaths, according to Johns Hopkins University’s COVID-19 dashboard.

Oncotelic Therapeutics, Inc. (OTLC) recently announced that its COVID-19 trial (“C001”) for OT-101 has successfully met its safety and efficacy endpoints.

OT-101 is a first-in-class anti-TGF-β ribonucleic acid (“RNA”) therapeutic that has exhibited single agent activity in relapsed/refractory cancer patients in multiple clinical trials. OT-101 has also demonstrated activity against the SARS-CoV-2 virus, the virus that causes COVID-19, and is currently being evaluated in the Company’s C001 clinical trial against hospitalized severe COVID-19 patients.

Both tumor cells and SARS-Cov-2 induce TGF-β as part of their immune evasion mechanism. Consequently, inhibiting TGF-β by OT-101 is expected to impact both cancer and COVID. By targeting the host protein, OT-101 is expected to work against multiple respiratory viruses, including related emerging variants, unlike traditional antiviral drugs and vaccines.

On October 18, Data lock and Study Data and Analysis Data Models (SDTMs & ADaMS Databases) were generated for a Phase 2 C001 Covid Study: “A Double-Blind, Randomized, Placebo Controlled, Multi-Center Study of OT-101 in Hospitalized COVID-19 Subjects”. The trial compares OT-101 + Standard of Care (“SOC”) versus Placebo + SOC (N= 32 pts at 2:1 randomization ratio). SOC includes dexamethasone, the only drug known to improve outcomes in severe cases of COVID-19. The top line data is:

1)  Safety endpoints met. OT-101 as a TGF-β inhibitor was safe to administer to COVID-19 patients including severe/critical COVID-19 patients.

2) Efficacy signals were obtained. End of treatment (Day 7) mortality for the entire study population was 4.5% OT-101 versus 20% for placebo.

3)  Incidence of >96% viral load knockdown on End of Treatment (Day 7) was 89% for OT-101 versus 67% for placebo.

4)  Overall survival improved 3X for critical COVID-19 pts (4 days for placebo versus 14 days for OT-101, p < 0.0166).

Roche’s (RHHBY) newly acquired subsidiary TIB Molbiol has developed three new test kits to help researchers detect mutations in the new Omicron variant of coronavirus, Roche said on Friday.

 

Pfizer (PFE) now expects to make 80 million courses of COVID drug Paxlovid by the end of 2022, Pfizer CEO Albert Bourla, Ph.D., told CNBC during a Monday interview. The company previously said it plans to have capacity to make 50 million courses.

Pfizer has filed Paxlovid for an FDA emergency use authorization and has signed a contract to provide 10 million courses to the U.S. government by 2022 for $5.29 billion.

Gilead Sciences (GILD) said new findings of its antiviral Veklury, a.k.a. remdesivir, showed the treatment is expected to remain effective against the omicron variant, Fox Business reports. An analysis of more than 200 available sequences of the strain, including those from South Africa, Asia and Europe, found no new mutations present in the variant expected to alter the viral RNA polymerase the antiviral targets. The biotech will continue to conduct in vitro lab testing of remdesivir against the omicron variant.

Merck & Co Inc’s (MRK) experimental COVID-19 drug molnupiravir should have similar activity against any new coronavirus variant, a company executive said on Tuesday.

The drug, developed along with Ridgeback Biotherapeutics, shows antiviral properties against coronavirus variants such as the Delta variant, Daria Hazuda, vice president of Merck’s infectious diseases and vaccines division, said.

Recent

A Host of Companies are Seeking to Make The Metaverse Happen: AXXA, NVDA, MTTR, U

Regardless of how markets perform next week or next month, there are some areas that should be very profitable over the long term. And...

These three penny stocks are very liquid and have been very popular among investors in the past

Penny stocks may be volatile, but with due diligence, some hidden treasures may be found.  These three penny stocks are very liquid and have been...

Golden Star Enterprises Ltd. (GSPT) saw new developments that hasn’t reflected in its shares price yet

Due to the pandemic, however, the importance of the technology sector increased enormously. In terms of industry specifics, IDC projects that the technology industry...

5 Covid Related Stocks To Consider This Month

Biogen Inc. (NASDAQ: BNTX) is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological,...

3 Entertainment Stocks To Consider Buying NOW: Cinedigm Corp., (CIDM), UMAX Group Corp. (UMAX), AMC Entertainment Holdings, Inc. (AMC)

The production and distribution of film and audiovisual works is one of the most dynamic growth sectors in the world. The world's entertainment and media...

3 Penny Stocks To Consider Before New Year: Asia Broadband Inc. (AABB), Two Hands Corporation (TWOH), US Energy Initiatives Corp (USEI)

Asia Broadband Inc. (OTC: AABB) is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian...

The Race for the Multi Billion Dollar Sport Nutrition Market is On

The Global Sports Nutrition Market was valued at $24.25B in the base year 2020, and is projected to reach $47.92B by 2027, with a...

These 4 Bitcoin Mining Stocks Offer an Alternative Way to Play Crypto

Bitcoin mining is the process of creating new bitcoin by solving puzzles. It consists of computing systems equipped with specialized chips competing to solve...

Astro Aerospace Ltd. (ASDN) Shares on Watch as The Market for Flying Cars is expected to Reach $1.5 Trillion by 2040

The market for flying cars, now known as electric air taxis, should continue to mature during this decade, soaring to $1.5 trillion globally by...

Stocks to Watch as Investors Monitor Omicron Variant

Covid-19 cases are surging worldwide and a number of countries have imposed fresh restrictions in an effort to curb the spread of a new...

3 CBD Stocks to Buy Ahead of the 3rd-Green Wave Rebound

As more and more states legalize marjiuana, federal legalization in the U.S. seems inevitable. Not only are more states passing legislation to permit recreational...

3 Nutritional Growth Stocks to Watch: Herbalife Nutrition (HLF), Torque Lifestyle Brands Inc. (TQLB) and Else Nutrition Holdings inc. (OTC: BABYF)

According to a recent report from Grand View Research, the global sports nutrition market size was valued at $10.7 billion in 2020 and is...

Sprouts Farmers Market Inc, (SFM) Two Hands Corporation, (TWOH) and United Natural Foods, Inc. (UNFI), on Watch as Food remains one of the thriving...

Food remains one of the thriving industries worldwide, given its essential business nature and a strong connection to consumers. In 2020, global food industry...